Avasare Rupali S, Rosenstiel Paul E, Zaky Ziad S, Tsapepas Demetra S, Appel Gerald B, Markowitz Glen S, Bomback Andrew S, Canetta Pietro A
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, N.Y., USA.
Am J Nephrol. 2017;45(2):99-106. doi: 10.1159/000453081. Epub 2017 Jan 6.
Most studies that have assessed the predictors of recurrent IgA nephropathy (IgAN) in the renal allograft have focused on post-transplant features. Identifying high-risk pre-transplant features of IgAN is useful for counseling patients and may help in tailoring post-transplant immunosuppression.
We investigated the pre-transplant clinical and biopsy features of 62 patients with IgAN who received transplants at Columbia University Medical Center from 2001 to 2012 and compared the characteristics and outcomes of patients with IgAN recurrence to those without recurrence. The primary outcome was time to recurrent IgAN. Secondary outcomes were a composite of doubling of creatinine or allograft failure, and recurrent IgAN as a cause of allograft dysfunction.
Of the 62 patients, 14 had recurrent IgAN in the allograft. Mean time to recurrence was 2.75 years. Those with recurrent disease were younger at the time of native kidney biopsy (29 vs. 41 years, p < 0.0009). Black race and Hispanic ethnicity composed a higher proportion of the recurrent disease group. On multivariable analysis, significant predictors of recurrent IgAN included age at diagnosis (hazards ratio (HR) 0.911, 95% CI 0.85-0.98), burden of crescents on native biopsy (HR 1.21 per 10% increase in crescents, 95% CI 1.00-1.47) and allograft rejection (HR 3.59, 95% CI 1.10-11.7).
Features of native IgAN can help predict the risk of recurrent disease in the renal allograft. In particular, immunologically active disease represented by earlier age of onset and greater burden of crescents on native biopsy is more likely to recur after transplant.
大多数评估肾移植中复发性IgA肾病(IgAN)预测因素的研究都集中在移植后的特征上。识别IgAN移植前的高危特征有助于为患者提供咨询,并可能有助于调整移植后的免疫抑制方案。
我们调查了2001年至2012年在哥伦比亚大学医学中心接受移植的62例IgAN患者的移植前临床和活检特征,并比较了IgAN复发患者和未复发患者的特征及结局。主要结局是至复发性IgAN的时间。次要结局是肌酐翻倍或移植肾失功的复合结局,以及复发性IgAN作为移植肾功能障碍的原因。
62例患者中,14例移植肾出现复发性IgAN。复发的平均时间为2.75年。复发患者在肾活检时年龄较小(29岁对41岁,p<0.0009)。黑人种族和西班牙裔在复发疾病组中所占比例更高。多变量分析显示,复发性IgAN的显著预测因素包括诊断时的年龄(风险比[HR]0.911,95%CI 0.85-0.98)、肾活检时新月体的比例(新月体每增加10%,HR 1.21,95%CI 1.00-1.47)和移植肾排斥反应(HR 3.59,95%CI 1.10-11.7)。
原发性IgAN的特征有助于预测肾移植中疾病复发的风险。特别是,以发病年龄较早和肾活检时新月体比例较高为代表的免疫活性疾病在移植后更有可能复发。